Pregnancy in patients with myelofibrosis: Mayo–Florence series of 24 pregnancies in 16 women

Gangat, Naseema; Guglielmelli, Paola; Al‐Kali, Aref; Wolanskyj, Alexandra P.; Camoriano, John; Patnaik, Mrinal M.; Pardanani, Animesh; Hanson, Curtis A.; Vannucchi, Alessandro M.; Tefferi, Ayalew

doi:10.1111/bjh.17626

Cited by 5 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The vast majority of our current knowledge in this field comes from literature data regarding ET patients, with less information available for PV and PMF. [26][27][28] It is important to note that even pregnancies occurring in healthy women have a definite risk of complications such as spontaneous abortion, stillbirth, or premature delivery, that is at least in part due to an increased risk of thrombosis, that is roughly six times higher as compared to healthy non pregnant women. 29 In healthy pregnancies there is, indeed, an overall rate of spontaneous abortion (defined as those events occurring up to the 20th week) of about 11%, accounting for 80% of all fetal losses, while stillbirth (defined as an intrauterine death occurring after the 20th week or birth of an infant showing no signs of life) occurs in 0.43% of cases.…”

Section: Introductionmentioning

confidence: 99%

Philadelphia chromosome-negative myeloproliferative neoplasms in younger adults: A critical discussion of unmet medical needs, with a focus on pregnancy

et al. 2022

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Philadelphia chromosome-negative myeloproliferative neoplasms in younger adults: A critical discussion of unmet medical needs, with a focus on pregnancy

et al. 2022

View full text Add to dashboard Cite

Pregnancy and childbirth outcomes in women with myeloproliferative neoplasms—a nationwide population-based study of 342 pregnancies in Sweden

et al. 2022

View full text Add to dashboard Cite

Pregnancy and childbirth in women with myeloproliferative neoplasms (MPN) are reported to be associated with maternal thrombosis, hemorrhage, and placental dysfunction. To assess the risks of adverse events in pregnancy in women with MPN, we performed a large population-based study using Swedish health care registers, and included all pregnancies that had reached gestational week 22 (prior to 2008, week 28) during the years 1973–2017 in women with MPN. Control pregnancies were matched 1:1 for age, calendar year, and parity. We identified 342 pregnancies in 229 women with MPN. Preterm birth was significantly increased in pregnancies in MPN, 14% compared to 4% of pregnancies in controls (p < 0.001). Correspondingly, low birth weight (<2500 g) was also significantly increased in MPN pregnancies (p = 0.042). Stillbirth was rare, with two events (0.6%) in MPN, none in controls. Maternal thrombotic complications occurred in three (1%) of the pregnancies in MPN patients, compared to none in controls. Pregnancy-related bleeding affected 14% of pregnancies in MPN and 9% in controls (p < 0.110). Cesarean section was significantly more common in pregnancies in MPN. Incidence was 12.2 per 100.000 pregnancies. In summary, preterm birth was an important complication in MPN pregnancies, while maternal complications were less common than previously reported.

show abstract

Successful pregnancy outcome in a patient with myelofibrosis receiving ruxolitinib treatment in the first trimester

Urosevic,

Dokic,

Percic

et al. 2024

Leukemia & Lymphoma

View full text Add to dashboard Cite

Pregnancy in patients with myelofibrosis: Mayo–Florence series of 24 pregnancies in 16 women

Cited by 5 publications

References 10 publications

Philadelphia chromosome-negative myeloproliferative neoplasms in younger adults: A critical discussion of unmet medical needs, with a focus on pregnancy

Philadelphia chromosome-negative myeloproliferative neoplasms in younger adults: A critical discussion of unmet medical needs, with a focus on pregnancy

Pregnancy and childbirth outcomes in women with myeloproliferative neoplasms—a nationwide population-based study of 342 pregnancies in Sweden

Successful pregnancy outcome in a patient with myelofibrosis receiving ruxolitinib treatment in the first trimester

Contact Info

Product

Resources

About